3 buy-rated ASX 200 shares that analysts love

These ASX 200 shares are highly rated by analysts…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you're interested in adding some ASX 200 shares to your portfolio this week, then the three listed below could be worth considering.

These ASX 200 shares have all been named as buys recently. Here's what you need to know about them:

Three people in a corporate office pour over a tablet, ready to invest.

Image source: Getty Images

Cochlear Limited (ASX: COH)

The first ASX 200 share to look at is Cochlear. It is one of the world's leading hearing solutions companies with a portfolio of industry-leading cochlear implant devices.

Goldman Sachs is a fan of Cochlear. In response to its recent full year results, the broker reiterated its buy rating with an improved price target of $247.00. Goldman believes that Cochlear will grow its net profit by "a +10% CAGR from FY22-25E."

Goodman Group (ASX: GMG)

Another ASX 200 share that could be a top option for investors is Goodman Group. It is one of the world's leading integrated commercial and industrial property companies.

Goodman has been growing at a strong rate for years thanks to its expertly constructed portfolio that gives it exposure to key growth markets such as ecommerce and logistics.

The team at Citi is bullish on Goodman and expects its strong growth to continue. The broker recently commented: "We revise medium-term earnings higher and see upside to FY23 guidance of 90.3c (11% EPS growth) driven by (1) another strong year of development earnings growth, (2) continued rise in management and investment income driven by high asset values and recent development completions."

Citi has a buy rating and $23.50 price target on the company's shares.

ResMed Inc. (ASX: RMD)

A final ASX 200 share to look at is ResMed. It is another industry leader, this time in the sleep treatment market.

Like the others, the company has been growing at a strong rate for years and has been tipped to continue doing so for the foreseeable future.

Morgans is a fan of ResMed. It believes there is "a multi-year opportunity for RMD to growth at or above market and solidify its market leadership position." The broker has an add rating and $37.08 price target on its shares.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear Ltd. and ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

Young woman thinking with laptop open.
Blue Chip Shares

Why is everyone selling Wesfarmers shares?

It looks like the retail conglomerate fell out of favour with investors this year.

Read more »

Four business people wearing formal business suits and ties walk abreast on a wide paved surface with their long shadows falling on the ground ahead of them.
Blue Chip Shares

How did these ASX blue-chip shares perform in March?

Did these blue-chips beat the market in March?

Read more »

Couple looking at their phone surprised, symbolising a bargain buy.
Blue Chip Shares

Are these ASX blue chips now too cheap to ignore?

Let's see why these shares could be seriously undervalued at current levels.

Read more »

A woman gives two fist pumps with a big smile as she learns of her windfall, sitting at her desk.
Blue Chip Shares

3 reasons to buy Wesfarmers shares today

The retail conglomerate is a no-brainer buy in my book.

Read more »

ASX shares buy Street signs stating 'Winners' and 'Losers' in front of urban backdrop
Blue Chip Shares

How are these 5 ASX share giants really tracking in 2026?

Some are struggling, while others are thriving, proving that opportunity is never far away.

Read more »

Happy work colleagues give each other a fist pump.
Blue Chip Shares

My best blue-chip ASX 200 buys for April

Looking for quality in uncertain markets? These three ASX 200 shares stand out to me.

Read more »

A woman scratches her head, thinking is this a no-brainer?
Healthcare Shares

Does this ASX 200 stock's fall make it a no-brainer buy?

Despite a major transformation, this stock is down more than 20%. Is this an opportunity?

Read more »

A happy woman stands outside a building looking at her phone and smiling widely.
Blue Chip Shares

I think smart investors should buy these ASX 200 blue-chip shares with $10,000

Looking for ideas? Here are three ASX 200 blue chips that could help build long-term wealth.

Read more »